Hide metadata

dc.date.accessioned2022-11-10T17:44:51Z
dc.date.available2022-11-10T17:44:51Z
dc.date.created2022-08-17T10:11:03Z
dc.date.issued2022
dc.identifier.citationKared, Hassen Wolf, Asia-Sophia Fumika Michaela Alirezaylavasani, Amin Ravussin, Anthony Solum, Guri Tran, Trung The Lund-Johansen, Fridtjof Vaage, John T. Nissen-Meyer, Lise Sofie Haug Nygaard, Unni Cecilie Hungnes, Olav Robertson, Anna Hayman Næss, Lisbeth Meyer Trogstad, Lill Magnus, Per Minor Munthe, Ludvig Andre Mjaaland, Siri . Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nature Communications. 2022, 13(1), 1-12
dc.identifier.urihttp://hdl.handle.net/10852/97551
dc.description.abstractAbstract The SARS-CoV-2 Omicron variant has more than 15 mutations in the receptor binding domain of the Spike protein enabling increased transmissibility and viral escape from antibodies in vaccinated individuals. It is unclear how vaccine immunity protects against Omicron infection. Here we show that vaccinated participants at a super-spreader event have robust recall response of humoral and pre-existing cellular immunity induced by the vaccines, and an emergent de novo T cell response to non-Spike antigens. Individuals with Omicron SARS-CoV-2 breakthrough infections have significantly increased activated SARS-CoV-2 wild type Spike-specific cytotoxic T cells, activated follicular helper (T FH ) cells, functional T cell responses, boosted humoral responses, and rapid release of Spike and RBD-specific IgG + B cell plasmablasts and memory B cells into circulation. Omicron breakthrough infection affords significantly increased de novo memory T cell responses to non-Spike viral antigens. Concerted T and B cell responses may provide durable and broad immunity.
dc.languageEN
dc.publisherNature Portfolio
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleImmune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
dc.title.alternativeENEngelskEnglishImmune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults
dc.typeJournal article
dc.creator.authorKared, Hassen
dc.creator.authorWolf, Asia-Sophia Fumika Michaela
dc.creator.authorAlirezaylavasani, Amin
dc.creator.authorRavussin, Anthony
dc.creator.authorSolum, Guri
dc.creator.authorTran, Trung The
dc.creator.authorLund-Johansen, Fridtjof
dc.creator.authorVaage, John T.
dc.creator.authorNissen-Meyer, Lise Sofie Haug
dc.creator.authorNygaard, Unni Cecilie
dc.creator.authorHungnes, Olav
dc.creator.authorRobertson, Anna Hayman
dc.creator.authorNæss, Lisbeth Meyer
dc.creator.authorTrogstad, Lill
dc.creator.authorMagnus, Per Minor
dc.creator.authorMunthe, Ludvig Andre
dc.creator.authorMjaaland, Siri
cristin.unitcode185,53,18,12
cristin.unitnameImmunologi og transfusjonsmedisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin2043714
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature Communications&rft.volume=13&rft.spage=1&rft.date=2022
dc.identifier.jtitleNature Communications
dc.identifier.volume13
dc.identifier.issue1
dc.identifier.doihttps://doi.org/10.1038/s41467-022-31888-y
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2041-1723
dc.type.versionPublishedVersion
cristin.articleid4165


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International